Business Context and Reporting Period
CareDx, Inc. filed a Form 8-K Current Report on June 13, 2016. The filing discloses a material event under Regulation FD regarding the clinical validity of the company's AlloSure test for acute rejection in a prospective multi-center kidney transplant study.
Key Financial Metrics
This filing is a current report focused on a specific corporate event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material change reported is the announcement of clinical study results for the AlloSure test. The company confirmed the clinical validity of the test for detecting acute rejection in kidney transplant patients based on a prospective multi-center study.
Guidance, Outlook, and Management Commentary
- Management Action: The company held a conference call on June 13, 2016, to discuss the study results.
- Disclosure Status: The press release detailing the results is attached as Exhibit 99.1. The filing explicitly states that this information is furnished under Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
- Outlook: No specific financial guidance or forward-looking projections are included in this text.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific statistical data regarding the AlloSure study results.
- Verify the clinical endpoints and methodology of the prospective multi-center kidney transplant study.
- Check subsequent filings for any regulatory updates or commercialization plans resulting from these study results.